Eton Pharmaceuticals out-licenses Increlex global rights to Esteve
Increlex is a biologic therapy for children aged 2–18 with severe primary insulin-like growth factor-1 deficiency
Alnylam’s Qfitlia receives FDA nod for haemophilia A and B treatment
Novartis gets FDA approval for Pluvicto to treat advanced prostate cancer
AstraZeneca gets FDA nod for Imfinzi regimen to treat MIBC
Scinai to acquire Pincell for its rare skin disease drug PC111
Genmab’s Tivdak approved in Japan to treat cervical cancer
Analysis
View More
Risks
View MoreSocietal polarisation and its impact on the pharmaceutical industry
Societal polarisation presents significant challenges for the pharmaceutical industry, affecting regulatory landscapes, public trust, innovation, and market dynamics
Effects of interstate armed conflicts on the pharmaceutical industry
Unveiling the impact of misinformation and disinformation in the pharmaceutical industry
The ripple effects of inflation on the pharmaceutical industry
Extreme weather events: The implications for the pharmaceutical industry